Harmony Biosciences Holdings (HRMY) — Cash Flow-to-Debt Ratio
Harmony Biosciences Holdings (HRMY) has a Cash Flow-to-Debt Ratio of 0.25x as of June 2026, meaning its operating cash flow of $92.43 Million could theoretically repay 0% of its total liabilities ($373.84 Million) in one year. See HRMY FCF to total liabilities ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Harmony Biosciences Holdings Cash Flow-to-Debt Ratio (2018–2025)
Historical debt coverage capacity for Harmony Biosciences Holdings across 8 annual periods. For the full cash flow conversion analysis, see HRMY cash flow conversion.
Annual Cash Flow-to-Debt Ratio for Harmony Biosciences Holdings (2018–2025)
Year-by-year debt coverage analysis for Harmony Biosciences Holdings. Check HRMY cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.87x | $348.20 Million | $401.41 Million | ▲ +34.2% |
| 2024 | 0.65x | $219.82 Million | $340.05 Million | ▲ +1.5% |
| 2023 | 0.64x | $219.39 Million | $344.46 Million | ▲ +19.5% |
| 2022 | 0.53x | $144.47 Million | $271.03 Million | ▲ +33.5% |
| 2021 | 0.40x | $98.56 Million | $246.94 Million | ▲ +4511.0% |
| 2020 | -0.01x | $-2.98 Million | $329.89 Million | ▲ +98.6% |
| 2019 | -0.64x | $-75.44 Million | $118.29 Million | ▲ +87.3% |
| 2018 | -5.00x | $-38.80 Million | $7.75 Million | — |